Join MediWound (#MDWD) for a virtual Key Opinion Leader (KOL) event on Wed, Jan. 8 at 10am ET to discuss EscharEx®, an innovative treatment in late-stage clinical development for chronic wound debridement, with a focus on its upcoming Phase III VALUE study in venous leg ulcers (VLUs). The event will feature three distinguished experts. Register here: https://bit.ly/3DiQ0OE
LifeSci Advisors, LLC
Financial Services
New York, New York 15,539 followers
Accelerating Innovations In Life Science.
About us
LifeSci Advisors is a unique investor relations consultancy founded to provide companies in the life sciences field with a comprehensive solution to investor communications and outreach. Our services are designed to increase our clients’ visibility within the investment community and to educate investors about the opportunity. We strive to effectively communicate each clients’ unique value proposition, building momentum for the investment. We begin with deep due diligence as we partner with each client to gain an unparalleled level of understanding of their business and the opportunities they are addressing. This in-depth knowledge allows us to be able to provide each client partner with thoughtful recommendations related to corporate communications, investor outreach, and capital markets planning. Our strategies and actions are specifically tailored to help each client achieve their investor relations goals.
- Website
-
http://www.lifesciadvisors.com
External link for LifeSci Advisors, LLC
- Industry
- Financial Services
- Company size
- 51-200 employees
- Headquarters
- New York, New York
- Type
- Privately Held
- Founded
- 2009
- Specialties
- Investor Relations
Locations
-
Primary
Get directions
250 W 55th St
#3401
New York, New York 10019, US
Employees at LifeSci Advisors, LLC
-
Anne Chofflet
-
Guillaume van Renterghem
Managing Director at LifeSci Advisors
-
Paul Arndt, MBA
Investor Relations Executive | Specializing in Biotech and Life Sciences | Building Strategic Partnerships and Delivering Market Insights
-
Vicki Campbell
Creative Director Specializing in Biomedical Graphics
Updates
-
TOMORROW! Don't miss the virtual KOL panel discussion hosted by Nusano at 1:00 PM ET. The event will feature Elcin Zan, MD (Cleveland Clinic) and Brian Zeglis (Hunter College), who will discuss emerging trends shaping the Radioligand Therapy (RLT) landscape, including the latest advancements and exciting developments on the horizon for 2025. Click here to register: https://lnkd.in/gGK56qbR
☃️ Before logging off for the holidays, don't miss your chance to hear what lies ahead for rapidly-changing field of radiopharmaceuticals. Join experts Elcin Zan, MD (Cleveland Clinic) and Brian Zeglis (Hunter College) for a free KOL event on Tuesday, December 17 at 1:00 PM Eastern, presented by Nusano & LifeSci Events.
This content isn’t available here
Access this content and more in the LinkedIn app
-
Join IDEAYA Biosciences (#IDYA) for a virtual Investor R&D Day on Monday, Dec 16 at 8am ET, featuring key opinion leaders who will join company management to showcase scientific insights and clinical development opportunities across IDEAYA’s precision medicine oncology pipeline. Register here: https://bit.ly/4gwBTDJ
-
-
Join PDS Biotechnology (#PDSB) for a virtual KOL event on Tues, Dec. 17 at 12pm ET with Dr. Frank Worden (Rogel Cancer Center, University of Michigan) and Dr. Kevin Harrington (The Institute of Cancer Research, United Kingdom) to discuss the pathology and growing prevalence of HPV16-positive head and neck squamous cell carcinoma (“HNSCC”), as well as the Company’s upcoming VERSATILE-003 Phase 3 clinical trial of Versamune® HPV + pembrolizumab for first-line treatment of recurrent and/or metastatic HPV16-positive HNSCC. Register here: https://bit.ly/3VyicDA
-
-
Don't miss the virtual KOL event hosted by Tectonic Therapeutic, Inc. on Thurs, Dec. 12th from 4-6 p.m. ET, featuring John Teerlink, MD, FHFSA (University of California San Francisco) and Raymond L. Benza MD, F.A.C.C., FAHA, FACP (Icahn School of Medicine at Mount Sinai). Register here: https://lnkd.in/ec-C2exC
Join us on Thurs Dec 12 from 4-6 p.m. ET for a discussion on the unmet need in Group 2 Pulmonary Hypertension due to Heart Failure with Preserved Ejection Fraction (Group 2 PH-HFpEF) and our lead program, TX45, as a potential treatment. We're looking forward to this event with John Teerlink, MD, FHFSA (University of California San Francisco) and Raymond L. Benza MD, F.A.C.C., FAHA, FACP (Icahn School of Medicine at Mount Sinai) #Group2PAH #GPCR #relaxin For more details: https://lnkd.in/e9UPQC-H Click here for free registration: https://lnkd.in/ec-C2exC
-
-
We look forward to hosting our 14th Annual Corporate Access Event in San Francisco next month. Register now: https://lnkd.in/eRDhJvqJ This premier event will showcase over 150 publicly traded and privately held companies across the healthcare industry. Event Highlights: - Date: Monday, January 13 - Wednesday, January 15, 2025 - Location: Beacon Grand Hotel, 450 Powell St, San Francisco, CA - Featuring Leading Companies In: Biotechnology, MedTech, Pharmaceuticals, Specialty Pharmaceuticals, Life Sciences, and Digital Health LifeSci Partners
-
-
Don't miss the Ligand Pharmaceuticals Investor Day in Boston next Tuesday, December 10th at 10:30 AM ET! Register here: https://lnkd.in/eUXpxUcA
We are excited to host our annual Investor Day in Boston next week. Ligand’s senior management team will provide an in-depth review of our progress and financial performance over the past 12 months and outline our growth strategy and financial outlook for 2025 and beyond. A live webcast and replay will be available. To learn more and register: https://ow.ly/rUaL50UjUOQ
-
-
Join Opus Genetics (#IRD) for a virtual KOL event on Wed, Dec. 11 at 4pm ET featuring Jean Bennett and Tomas Aleman, MD, from the University of Pennsylvania, along with Christine Kay and Arshad M. Khanani, who will discuss the new 6-month efficacy and safety data of OPGx-LCA5, an adeno-associated virus (AAV)-based gene therapy in Phase 1/2 development for LCA5-associated inherited retinal disease (IRD). Register here: https://bit.ly/3D0EgAs
-
-
We’re #hiring a new $2bn Healthcare Growth Venture Fund | (Senior) Associate in Austin, Texas Metropolitan Area. Apply today or share this post with your network.